Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
GSK will pay Hengrui $500 million upfront to start the alliance. In return, it will receive rights outside of the greater China region and Taiwan to an…
GSK said Monday it would pay $500 million upfront for rights to an experimental COPD drug from Jiangsu Hengrui Pharmaceuticals, the latest example of a pharma…
A Jefferies report found one-third of pharma licensing deal spending in H1 2025 involved China-originated drugs, up from 21% in prior years, raising…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
GSK licensed a potential best-in-class PDE3/4 inhibitor HRS-9821 for COPD from Hengrui Pharma, plus agreements to develop up to 11 additional programs across respiratory, immunology/inflammation, and oncology. GSK paid $500M upfront for the PDE3/4 program. Total potential value up to ~$12B if all programs are optioned and all milestones achieved. Hengrui leads development through Phase 1 completion.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GSK plc / Jiangsu Hengrui Pharmaceuticals Co. Ltd. (this deal) | 2025 | $12.0B | 65 |
| GSK plc / SmithKline Beecham | 2000 | $12.0B | 79 |
| GSK plc / Pfizer Inc. | 2018 | $0.0M | 77 |
| GSK plc / Novartis AG | 2014 | $16.0B | 76 |
| GSK plc / Hansoh Pharmaceutical Group Co. Ltd. | 2023 | $1.7B | 74 |
| GSK plc / Nuvalent, Inc. | 2026 | $10.6B | 70 |
| GSK plc / Sierra Oncology Inc. | 2022 | $1.9B | 70 |
← Browse all deals · How we score deals
More: 2025 deals · GSK plc deals · Respiratory deals